NLRP3 and metabolic dysfunction-associated steatohepatitis: Moreover, TGR5 agonists increase the phosphorylation of PKA and induce ubiquitination of NLRP3 inflammasome, which inhibits NLRP3-mediated M1 macrophage polarization, thereby alleviating liver steatosis and inflammation in NASH [89].